IQV:NYE-IQVIA Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 158.08

Change

-5.35 (-3.27)%

Market Cap

USD 31.51B

Volume

1.31M

Average Target Price

USD 186.64 (+18.06%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-02-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

-11.79 (-3.52%)

USD129.58B 35.24 22.81
DHR-PA Danaher Corporation

-24.48 (-2.00%)

USD112.44B 301.55 193.50
DHR Danaher Corporation

-5.06 (-3.13%)

USD109.07B 38.68 26.15
PHG Koninklijke Philips N.V

-1.64 (-3.42%)

USD41.07B 29.34 -147.85
A Agilent Technologies, Inc

-4.57 (-5.37%)

USD24.96B 33.31 21.72
LH Laboratory Corporation of Amer..

-2.01 (-1.06%)

USD18.43B 22.70 12.84
MTD Mettler-Toledo International I..

-33.64 (-4.43%)

USD18.29B 33.83 24.71
DGX Quest Diagnostics Incorporated

-0.81 (-0.72%)

USD14.99B 17.90 12.58
WAT Waters Corporation

-6.31 (-2.92%)

USD13.54B 24.17 18.29
PKI PerkinElmer, Inc

-4.23 (-4.56%)

USD9.85B 43.48 19.57

ETFs Containing IQV

Symbol Name Weight Mer Price(Change) Market Cap
GNRX VanEck Vectors Generic Dr.. 9.36 % 0.55 %

N/A

USD3.35M
BBH VanEck Vectors Biotech ET.. 5.54 % 0.35 %

-3.18 (-2.20%)

USD0.34B
FBU:CA CI First Asset U.S. Buyba.. 2.63 % 0.84 %

-1.17 (-3.71%)

USD0.02B
RYH Invesco S&P 500 Equal Wei.. 1.74 % 0.40 %

-6.79 (-2.97%)

USD0.77B
VOT Vanguard Mid-Cap Growth I.. 1.16 % 0.07 %

-5.10 (-3.03%)

USD15.51B
PBI Pitney Bowes Inc 0.00 % 0.00 %

-0.19 (-4.96%)

USD0.62B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

-1.14 (-3.54%)

USD8.62M

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.31% 68% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.31% 68% D+ 72% C-
Trailing 12 Months  
Capital Gain 10.96% 56% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.96% 56% F 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.23% 56% F 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.23% 38% F 84% B
Risk Return Profile  
Volatility (Standard Deviation) 16.94% 44% F 45% F
Risk Adjusted Return 95.81% 50% F 83% B
Market Capitalization 31.51B 79% C+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 170.24 13% F 3% F
Price/Book Ratio 5.24 37% F 18% F
Price / Cash Flow Ratio 22.24 42% F 16% F
EV/EBITDA 22.87 21% F 16% F
Management Effectiveness  
Return on Equity 3.44% 32% F 31% F
Return on Invested Capital 4.29% 26% F 36% F
Return on Assets 2.39% 26% F 47% F
Debt to Equity Ratio 192.82% 11% F 16% F
Technical Ratios  
Short Ratio 2.30 83% B 51% F
Short Percent 1.38% 83% B 84% B
Beta 0.90 74% C 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector